PATENT CLAIM ANALYSIS

Application Number: 16079596
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["514", "456000"]

Abstract:
The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.

Claim (Index 50):
The method of reducing the risk of cardiovascular death in a human of  claim 46 , wherein, the pharmaceutical composition comprises from 2 to 20 mg of ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 96.0
- Lexical Diversity: 1.65217
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15523512', '12546306', '14435730', '15576452', '13813045']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7983847642904006
- 35 USC 102 Novelty (BERT): 0.5641302756671699
- Combined Prediction Score: 0.7749593154280775
- Mean Citation Score: 299.864738
- Max Citation Score: 463.08795
- Similarity Product: 349.0973252141207

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test